Scarica l'app Stockscreener
5.72
5.30%
-0.32
Precedente Chiudi:
$6.04
Aprire:
$6.11
Volume 24 ore:
324.15K
Relative Volume:
0.79
Capitalizzazione di mercato:
$256.19M
Reddito:
$84.82M
Utile/perdita netta:
$-21.43M
Rapporto P/E:
-11.67
EPS:
-0.49
Flusso di cassa netto:
$-27.23M
1 W Prestazione:
-8.33%
1M Prestazione:
-7.59%
6M Prestazione:
-58.70%
1 anno Prestazione:
-65.27%
Intervallo 1D:
$5.67
$6.174
Intervallo di 1 settimana:
$5.67
$6.565
Portata 52W:
$5.60
$20.90
Y Mabs Therapeutics Inc Stock (YMAB) Company Profile
Nome
Y Mabs Therapeutics Inc
Settore
Industria
Telefono
212-847-9841
Indirizzo
230 PARK AVENUE, NEW YORK, NY
Confronta YMAB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
YMAB
Y Mabs Therapeutics Inc
|
5.72 | 256.19M | 84.82M | -21.43M | -27.23M | -0.49 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-18 | Iniziato | Oppenheimer | Outperform |
| 2024-08-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-06-28 | Iniziato | Truist | Buy |
| 2023-05-10 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2023-04-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-01-27 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2023-01-05 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-12-02 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-10-31 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-10-31 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-07-06 | Ripresa | Canaccord Genuity | Buy |
| 2022-06-24 | Iniziato | BMO Capital Markets | Outperform |
| 2022-02-03 | Ripresa | Guggenheim | Buy |
| 2021-11-19 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-11-16 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-05-07 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-04-23 | Ripresa | Cowen | Outperform |
| 2021-03-22 | Ripresa | JP Morgan | Overweight |
| 2021-01-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-11-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-05 | Iniziato | Barclays | Overweight |
| 2020-05-01 | Iniziato | Janney | Buy |
| 2020-04-29 | Iniziato | Morgan Stanley | Equal-Weight |
| 2019-12-24 | Iniziato | JP Morgan | Overweight |
| 2019-11-20 | Iniziato | Guggenheim | Buy |
| 2019-09-04 | Iniziato | Wedbush | Outperform |
| 2019-04-01 | Iniziato | H.C. Wainwright | Buy |
| 2018-10-16 | Iniziato | BTIG Research | Buy |
| 2018-10-16 | Iniziato | BofA/Merrill | Buy |
Mostra tutto
Y Mabs Therapeutics Inc Borsa (YMAB) Ultime notizie
Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025 - The Manila Times
Y-mAbs Therapeutics, Inc. to Announce Fourth Quarter and Full Year 2024 Results on March 4, 2025 - Nasdaq
When Will Y-mAbs Report Q4 Earnings? Key Date for Biotech Investors - StockTitan
(YMAB) Trading Signals - Stock Traders Daily
Layoff Tracker: Encoded Lays Off 29% of Employees - BioSpace
YMAB Stock Touches 52-Week Low at $5.69 Amid Market Challenges - MSN
Brain Cancer Market Expected to rise, 2034 | Y-mAbs Therapeutics - openPR
When the Price of (YMAB) Talks, People Listen - Stock Traders Daily
After Falling -15.24% During The Past Week, Should You Still Buy Oruka Therapeutics Inc (NASDAQ: ORKA)? - Marketing Sentinel
Y-Mabs Therapeutics Inc (NASDAQ: YMAB) Stock Has Dropped -21.18% Over The Month – Is There Room For Growth? - Marketing Sentinel
Mineralys Therapeutics Inc (NASDAQ: MLYS): Can The Stock Still Lose Despite An -20.31% YTD Loss? - Marketing Sentinel
Now Is The Time To Build A Position In Health In Tech Inc (NASDAQ:HIT) - Marketing Sentinel
Should You Expect Akero Therapeutics Inc (NASDAQ:AKRO) To Recover From Its 70.02% Gain From Highs? - Marketing Sentinel
ScanTech AI Systems Inc (NASDAQ: STAI) Gain Of 9.66% Compared To 52-Week Low; YTD Fall -84.49% – What Should You Do Now? – Marketing Sentinel - Marketing Sentinel
Apogee Therapeutics Inc (NASDAQ: APGE) Recovered 16.57% From The 52-Week Low, And Now It’s -12.32% YTD – This Is What You Do Now – Marketing Sentinel - Marketing Sentinel
Now Is The Time To Build A Position In SolarBank Corporation (NASDAQ:SUUN) - Marketing Sentinel
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $20.89 Average Price Target from Analysts - MarketBeat
YmAbs Therapeutics (YMAB) Loses -25.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Y-Mabs Therapeutics Inc (YMAB) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Y-mAbs to Present at the Oppenheimer 35ᵗʰ Annual Life Sciences Conference - The Manila Times
Cancer Treatment Pioneer Y-mAbs Takes Center Stage at Major Healthcare Conference - StockTitan
Brain Cancer Market Report 2034: Epidemiology Data, Pipeline - openPR
Analytical Overview: Y-Mabs Therapeutics Inc (YMAB)’s Ratios Tell a Financial Story - The Dwinnex
An Overview of Castellum Inc (AMEX: CTM)’s Stock Performance and Outlook - Marketing Sentinel
A stock that deserves closer examination: Y-Mabs Therapeutics Inc (YMAB) - US Post News
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Now Is The Time To Build A Position In Outlook Therapeutics Inc (NASDAQ:OTLK) - Marketing Sentinel
YmAbs Therapeutics (YMAB) Loses -26.93% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
YMAB stock touches 52-week low at $6 amid challenging year - MSN
Jasper Therapeutics Inc (NASDAQ:JSPR) Drops -9.55%, But A Strong Recovery May Be Imminent - Marketing Sentinel
Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting - The Manila Times
Groundbreaking Cancer Treatment Data: Y-mAbs' GD2-SADA Shows Remarkable Preclinical Results - StockTitan
Y-mAbs Therapeutics' SWOT analysis: innovative cancer therapy stock faces growth hurdles - MSN
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Position Boosted by JPMorgan Chase & Co. - Defense World
Y-mAbs Therapeutics’ SWOT analysis: innovative cancer therapy stock faces growth hurdles - Investing.com Nigeria
(YMAB) Trading Report - Stock Traders Daily
Y-mAbs Therapeutics: Finding Direction Through The Murk Of Clinical Trials - Seeking Alpha
Cantor Fitzgerald Weighs in on YMAB FY2025 Earnings - Defense World
Cantor Fitzgerald Predicts YMAB FY2025 Earnings - MarketBeat
Contrasting Lotus Pharmaceuticals (OTCMKTS:LTUS) and Y-mAbs Therapeutics (NASDAQ:YMAB) - Defense World
Now Is The Time To Build A Position In Capricor Therapeutics Inc (NASDAQ:CAPR) - Marketing Sentinel
Now Is The Time To Build A Position In NewGenIvf Group Ltd (NASDAQ:NIVF) - Marketing Sentinel
XORTX Therapeutics Inc (NASDAQ:XRTX) Plunging -39.23% In 6 Months – Here’s What To Expect - Marketing Sentinel
Barclays PLC Increases Stock Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Y-mAbs Therapeutics Releases Corporate Overview PresentationOn January 13, 2025, Y-mAbs Therapeutics, Inc. disclosed a corporate overview presentation on its investor relations website, https://ir.ymabs.com. The presentation is intended for investor - Defense World
Y-mAbs Therapeutics’ (YMAB) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Y-mAbs Therapeutics Updates on Business and Clinical Trials - TipRanks
Y-mAbs Therapeutics (NASDAQ:YMAB) Given "Buy" Rating at HC Wainwright - MarketBeat
Y-mAbs Therapeutics Announces Business Realignment Plan and Preliminary 2024 Financial ResultsOn January 6, 2025, Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) revealed a business realignment plan aimed at maximizing operational efficiencies. The p - Defense World
Y-mAbs Therapeutics (NASDAQ:YMAB) Earns Outperform Rating from Wedbush - Defense World
Y-mAbs Therapeutics Announces Strategic Business Realignment - Yahoo Finance
Y Mabs Therapeutics Inc Azioni (YMAB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Y Mabs Therapeutics Inc Azioni (YMAB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Gad Thomas | CHIEF BUSINESS OFFICER |
Sep 13 '24 |
Sale |
13.47 |
65,000 |
875,550 |
97,681 |
| Gad Thomas | CHIEF BUSINESS OFFICER |
Sep 16 '24 |
Sale |
12.97 |
30,000 |
389,100 |
67,681 |
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):